There are many studies at the molecular, biochemical, organism and clinical levels suggest that the inhibition of protein kinase C isomers (PKC) may be a possible novel approach for the treatment of bipolar disorder and specifically the mania pole of the disease.
Like tamoxifen,an antiestrogenic drug,as a kind of the PKC inhibitor,it shows antimanic effects in animals and human[2-3].However, tamoxifen may not be the ideal drug for the treatment of patients with affective disorders because it has a variety of biological properties.So it is necessary to look for a better PKC inhibitor with less side effects, especially ones that can penetrate the blood-brain barrier(BBB).
Some researches have proved that chelerythrine can also inhibit PKC and it is blood brain barrier (BBB) penetrable. Then, the question is coming:
Dose chelerythrine ease mania-related behavioral?
To further evaluate this possibility,a study was designed to test the effects of peripheral (intraperitoneal) administration of chelerythrine in a battery of mania-related behavioral tests in black Swiss mice.
In this study,researchers tested spontaneous activity, sweet solution preference, elevated plus maze(EPM), forced swim test(FST), and amphetamine-induced hyperactivity of mice.The results showed that the peripheral administration of the PKC inhibitor chelerythrine had some effects in the spontaneous activity test and in the sweet solution preference test but no effects in the EPM, the FST or the amphetamine-induced hyperactivity test.
These results cannot strongly support an antimanic effect of chelerythrine ,but do suggest the possibility that it may have some effects on specific behavioral domains of mania
In addition, interestingly, a recent paper found that a higher dose administered in a more chronic regimen in rats, did reduce amphetamine-induced hyperactivity, indicating that above-mentioned study the dose might have been too low.
In summary, chelerythrine can may be used to treat bipolar disorder and ease manic-like behavior, certainly, additional dose and time response studies need to do to evaluate its range of activity.
 Zarate CA, Manji HK. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 2009;23(7):569–82.
Einat H, Yuan P, Szabo ST, Dogra S, Manji HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007;55(3–4):123–31
Abrial E, Etievant A, Betry C, Scarna H, Lucas G, Haddjeri N, et al. Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats. Prog Neuropsychopharmacol Biol Psychiatry 2013;40–8.
Cervo L, Mukherjee S, Bertaglia A, Samanin R.Protein kinases A and C are involved in the mechanisms underlying consolidation of cocaine place conditioning. Brain Res 1997;775(1–2):30–6.
 Einat H. Partial effects of the protein kinase C inhibitor chelerythrine in a battery of tests for manic-like behavior in black Swiss mice.[J]. Pharmacological Reports Pr, 2014, 66(4):722-725.
 ] Abrial E, Etievant A, Betry C, Scarna H, Lucas G, Haddjeri N, et al. Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats. Prog Neuropsychopharmacol Biol Psychiatry 2013;40–8.
According to research, myricetin stimulates glucose transport in... More
BVC synergised with thiazolidinediones, which are synthetic PPAR... More
Cardiac hypertrophy is the myocardial response to various pathol... More